Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens-Reference-Cited by-同舟云学术

Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens

Published:2007-07 Issue:29 Volume:282 Page:20847-20853
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Shiryaev Sergey A.,Remacle Albert G.,Ratnikov Boris I.,Nelson Nicholas A.,Savinov Alexei Y.,Wei Ge,Bottini Massimo,Rega Michele F.,Parent Amelie,Desjardins Roxane,Fugere Martin,Day Robert,Sabet Mojgan,Pellecchia Maurizio,Liddington Robert C.,Smith Jeffrey W.,Mustelin Tomas,Guiney Donald G.,Lebl Michal,Strongin Alex Y.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference35 articles.

1. Furin at the cutting edge: From protein traffic to embryogenesis and disease

2. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition

3. Proprotein convertases: lessons from knockouts

4. Anthrax Toxin

5. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Prospects of Furin Inhibitors for Therapeutic Applications;International Journal of Molecular Sciences;2024-08-24

2. Evaluation of Potential Furin Protease Inhibitory Properties of Pioglitazone, Rosiglitazone, and Pirfenidone: An In Silico Docking and Molecular Dynamics Simulation Approach;Current Issues in Molecular Biology;2024-08-08

3. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2;MedComm;2023-05-14

4. PAMAM–guanylthiourea conjugates mask furin's substrate binding site: mechanistic insights from molecular docking and molecular dynamics studies assist the design of potential furin inhibitors;New Journal of Chemistry;2023

5. A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2;Pharmacological Reports;2022-01-15